Alto Neuroscience Inc.
ANROStock
$27.33+937.31%52W
Market Cap$976.31M
P/E—
Div yield—
Beta2.36
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)75.67%
Price vs S&P 500 (4W)31.72%
VGM Score88.26
Market Capitalization$976.31M
Earnings Surprise History
Q1 26-0.80est. -0.55
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.31
4.31
4.31
4.39
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANROAlto Neuroscience Inc. | — | — | A | $27.33 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Alto Neuroscience is a clinical-stage biopharmaceutical company developing personalized psychiatric treatments guided by brain-based biomarkers. The company's pipeline includes multiple programs targeting major depressive disorder and schizophrenia, with candidates including ALTO-100, ALTO-202, ALTO-101, and ALTO-300. Alto's approach aims to match patients with treatments based on individual neurobiology to improve treatment efficacy in psychiatry.